Pharmacokinetics prediction and drugability assessment of diphenylheptanoids from turmeric (Curcuma longa L)

Medicinal Chemistry

Volumn 5, Issue 2, 2009, Pages 130-138

  Balaji, S ^a   Chempakam, B ^a  

^a INDIAN INSTITUTE OF SPICES RESEARCH   (India)

Author keywords

ADMET; Diphenylheptanoids; Drugability; Hepatotoxicity; Mutagenicity; Pharmacokinetics; Rodent carcinogenicity; Turmeric

Indexed keywords

1 (4 HYDROXY 3 METHOXYPHENYL) 7 (3,4 DIHYDROXYPHENYL) 1,6 HEPTADIENE 3,5 DIONE; 1,7 BIS (4 HYDROXY 3 METHOXYPHENYL) 1 HEPTENE 3,5 DIONE; 1,7 BIS (4 HYDROXY 3 METHOXYPHENYL) 1,4,6 HEPTATRIEN 3 ONE; 1,7 BIS (4 HYDROXYPHENYL) 1 HEPTEN 3,5 DIONE; 1,7 BIS (4 HYDROXYPHENYL) 1,4,6 HEPTATRIEN 3 ONE; 1,7 DIPHENYL 1 HEPTEN 5 ONE; 1,7 DIPHENYL 1,3 HEPTADIEN 5 OL; 1,7 DIPHENYL 1,3 HEPTADIEN 5 ONE; 1,7 DIPHENYL 3 HYDROXY 1 HEPTEN 5 ONE; 5 HYDROXY 7 (4 HYDROXYPHENYL) 1 PHENYL 1 HEPTENE; 5' METHOXYCURCUMIN; 7 (3,4 DIHYDROXYPHENYL) 5 HYDROXY 1 PHENYL 1 HEPTENE; 7 HYDROXY 1,7 BIS (4 HYDROXY 3 METHOXYPHENYL) 1 HEPTENE 3,5 DIONE; BIS DEMETHOXYCURCUMIN; CURCUMIN; CURCUMIN DERIVATIVE; CYCLOCURCUMIN; DEMETHOXYCURCUMIN; DIHYDROCURCUMIN; DIPHENYLHEPTANOID DERIVATIVE; PLANT MEDICINAL PRODUCT; TETRAHYDRO BIS DEMETHOXYCURCUMIN; TETRAHYDRODEMETHOXYCURCUMIN; UNCLASSIFIED DRUG; ALKENE; BIPHENYL DERIVATIVE; CYTOCHROME P450 2D6; DRUG DERIVATIVE; PLASMA PROTEIN;

ANIMAL CELL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INFORMATION; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; HUMAN; HUMAN CELL; LIVER TOXICITY; MUTAGENICITY; NONHUMAN; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; BIOLOGY; BLOOD BRAIN BARRIER; CARCINOGEN TESTING; CELL STRAIN CACO 2; CHEMISTRY; CURCUMA LONGA; DOG; DRUG EFFECT; INTESTINE ABSORPTION; LIVER; METABOLISM; MOUSE; MUTAGEN TESTING; PERMEABILITY; RAT; SKIN ABSORPTION; SOLUBILITY;

ALKENES; ANIMALS; BIPHENYL COMPOUNDS; BLOOD PROTEINS; BLOOD-BRAIN BARRIER; CACO-2 CELLS; CARCINOGENICITY TESTS; COMPUTATIONAL BIOLOGY; CURCUMA; CURCUMIN; CYTOCHROME P-450 CYP2D6; DOGS; HUMANS; INTESTINAL ABSORPTION; LIVER; MICE; MODELS, BIOLOGICAL; MUTAGENICITY TESTS; PERMEABILITY; RATS; SKIN ABSORPTION; SOLUBILITY;

EID: 65349113674     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340609787582873     Document Type: Article

References (28)

1. Aggarwal, B.B.; Sundaram, C.; Malani, N.; Ichikawa, H. Curcumin: the Indian solid gold. Adv. Exp. Med. Biol., 2007, 595, 1-75.
2. Chattopadhyay, I.; Biswas, K.; Bandyopadhyay, U.; Banerjee, R.K. Turmeric and curcumin: Biological actions and medicinal applications. Curr. Sci., 2004, 87, 44-53.
3. Susnow, R.G.; Dixon, S.L. Use of robust classification techniques for the prediction of human cytochrome P450 2D6 Inhibition. J. Chem. Inf. Compt. Sci., 2003, 43, 1308-1315.
4. Chang, J. Medicinal herbs: drugs or dietary supplements? Biochem. Pharmacol., 2000, 59, 211-219.
5. Littleton, J.; Rogers, T.; Falcone, D. Novel approaches to plant drug discovery based on high throughput pharmacological screening and genetic manipulation. Life Sci., 2005, 78, 467-475.
6. Manju, S. Agricultural Biotechnology and the Poor. In India: Biotechnology Research and Development, Department of Biotechnology, Government of India: New Delhi, 2000; pp. 51-57.
7. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods., 2000, 44, 235-249.
8. Veber, D.F.; Johnson, S.R.; Cheng, H.Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 2002, 45, 2615-2623.
9. Cheng, A.; Merz, K.M Jr. Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships. J. Med. Chem., 2003, 46, 3572-80.
10. Bohacek, R.S.; McMartin, C.; Guida, W.C. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev., 1996, 16, 3-50.
11. Hubbard, R.E. Can drugs be designed? Curr. Opin. Biotechnol., 1997, 8, 696-700.
12. Kubinyi, H. Structure-based design of enzyme inhibitors and receptor ligands. Curr. Opin. Drug Discov. Dev., 1998, 1, 4-15.
13. Murcko, M.A.; Caron, P.R.; Charifson, P.S. Structure-based drug design. Ann. Rep. Med. Chem., 1999, 34, 297-306.
14. Balogh, M.P. The Future of Drug Lead Development and Analysis, LCGC North America, 2007. http://www.lcgcmag.com/lcgc/
15. Krueger, T.E.; Buenger, P. The role of the therapeutic regimen in dosage design. Chemotherapia, 1965, 10, 61-73.
16. Peters, T. All about Albumin: Biochemistry, Genetics, and Medical Applications. Academic Press: San Diego, 1995.
17. Cannon, J.G. Pharmacology for chemists, Oxford University Press: London, 1999.
18. Holford, N.H.G.; Benet, L.Z. In Basic and Clinical Pharmacology, Katzung, B.G., Ed.; 7th Edition, Appleton and Lange: Stamford, CT, 1998.
19. Heydari, A.; Yeo, K.R; Lennard, M.S.; Ellis, S.W.; Tucker, G.T.; Rostami-Hodjegan, A. Mechanism-based inactivation of CYP2D6 by methylenedioxy-methamphetamine. Drug Metab. Dispos., 2004, 32, 1213-1217.
20. Mortelmans, K.; Zeiger, E. The Ames Salmonella/microsome mutagenicity assay, Mutat. Res., 2000, 455, 29-60.
21. Valerio, L.G.; Arvidson, K.B.; Chanderbhan, R.F.; Contrera, J.F. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling. Toxicol. Appl. Pharmacol., 2007, 222, 1-16.
22. Babu, P.S; Srinivasan, K. Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats. Mol. Cell. Biochem., 1997, 166, 169-175.
23. Kandarkar, S.V.; Sawant, S.S.; Ingle, A.D.; Deshpande, S.S.; Maru, G.B. Subchronic oral hepatotoxicity of turmeric in mice - histopathological and ultrastructural studies. Ind. J. Exp. Biol., 1998, 36, 675-679.
24. Fetrow, C.W.; Avila, J.R. Professional's handbook of complementary and alternative medicines. Springhouse, Springhouse Corporation: Pennsylvania, 1999.
25. Irvine, J.D.; Takahashi, L.; Lockhart, K.; Cheong, J.; Tolan, J.W.; Selick, H.E.; Grove, J.R. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci., 1999, 88, 28-33.
26. Helma, C.; Kramer, S. A survey of the Predictive Toxicology Challenge 2000-2001. Bioinformatics, 2003, 19, 1179-1182.
27. Benigni, R. The first US National Toxicology Program exercise on the prediction of rodent carcinogenicity: definitive results. Mutat. Res., 1997, 387, 35-45.
28. Lagunin, A.; Stepanchikova, A.; Filimonov, D.; Poroikov, V. PASS: prediction of activity spectra for biologically active substances. Bioinformatics, 2000, 16, 747-748.